Everestmab

N/A

Report date: 2022/01/05 15:24:33

Base Information

Drug NameEverestmab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesTongji Hospital
China Registration ClassN/A

Develop Information

Active CompaniesTongji Hospital
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A